AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myeloid, Acute
In brief
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML. We hypothesize that disrupting the interaction between AML blasts and the marrow microenvironment with AMD3100 may enhance the cytotoxic effect of chemotherapy.
Key facts
- Study ID
- NCT00512252
- Run by
- Washington University School of Medicine
- People needed
- 52
- Starts
- 2007-07-01
- Expected to finish
- 2010-06-01
- Last updated by the study team
- 2016-12-12
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Acute myeloid leukemia diagnosed by WHO criteria with one of the following:
- Primary refractory disease following >= 1 rounds of induction chemotherapy
- First relapse or higher
- Age between 18 and 70 years of age
- Adequate organ function defined as Creatinine <= 1.5 x institutional ULN; AST, ALT, total bilirubin <= 2 x ULN; Left ventricular ejection fraction of >= 40% by MUGA scan
- Women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study
- Able to provide signed informed consent prior to registration on study
You may not qualify if…
- Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)
- Peripheral blood blast count > 20 x 103 /mm3
- Active CNS involvement with leukemia
- Previous treatment with MEC or other regimen containing both mitoxantrone and etoposide
- Pregnant or nursing
- Receiving any other investigational agent
- Colony stimulating factors filgrastim, pegfilgrastim or sargramostim within 2 weeks of study
- Less than 2 weeks from the completion of any previous cytotoxic chemotherapy
- Severe concurrent illness that would limit compliance with study requirements
Where it is running
- Washington University — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.